145 related articles for article (PubMed ID: 23719953)
21. Identification of glycoproteins in human cerebrospinal fluid.
Hwang HJ; Quinn T; Zhang J
Methods Mol Biol; 2009; 566():263-76. PubMed ID: 20058177
[TBL] [Abstract][Full Text] [Related]
22. Biobanking of CSF: international standardization to optimize biomarker development.
Teunissen CE; Tumani H; Engelborghs S; Mollenhauer B
Clin Biochem; 2014 Mar; 47(4-5):288-92. PubMed ID: 24389077
[TBL] [Abstract][Full Text] [Related]
23. Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review).
Allegra A; Alonci A; Campo S; Penna G; Petrungaro A; Gerace D; Musolino C
Int J Oncol; 2012 Dec; 41(6):1897-912. PubMed ID: 23026890
[TBL] [Abstract][Full Text] [Related]
24. Neurochemical approaches of cerebrospinal fluid diagnostics in neurodegenerative diseases.
Otto M; Lewczuk P; Wiltfang J
Methods; 2008 Apr; 44(4):289-98. PubMed ID: 18374272
[TBL] [Abstract][Full Text] [Related]
25. Dosing, collection, and quality control issues in cerebrospinal fluid research using animal models.
Barten DM; Cadelina GW; Weed MR
Handb Clin Neurol; 2017; 146():47-64. PubMed ID: 29110779
[TBL] [Abstract][Full Text] [Related]
26. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages.
Sukata T; Sumida K; Kushida M; Ogata K; Miyata K; Yabushita S; Uwagawa S
Toxicol Lett; 2011 Jan; 200(1-2):46-52. PubMed ID: 21035526
[TBL] [Abstract][Full Text] [Related]
27. Cerebrospinal fluid microRNAs as diagnostic biomarkers in brain tumors.
Kopkova A; Sana J; Fadrus P; Slaby O
Clin Chem Lab Med; 2018 May; 56(6):869-879. PubMed ID: 29451858
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic microRNAs in stage II colon cancer.
Schepeler T; Reinert JT; Ostenfeld MS; Christensen LL; Silahtaroglu AN; Dyrskjøt L; Wiuf C; Sørensen FJ; Kruhøffer M; Laurberg S; Kauppinen S; Ørntoft TF; Andersen CL
Cancer Res; 2008 Aug; 68(15):6416-24. PubMed ID: 18676867
[TBL] [Abstract][Full Text] [Related]
29. MicroRNAs as biomarkers of disease onset.
Ciesla M; Skrzypek K; Kozakowska M; Loboda A; Jozkowicz A; Dulak J
Anal Bioanal Chem; 2011 Oct; 401(7):2051-61. PubMed ID: 21544542
[TBL] [Abstract][Full Text] [Related]
30. Whole-genome RT-qPCR microRNA expression profiling.
Mestdagh P; Derveaux S; Vandesompele J
Methods Mol Biol; 2012; 815():121-30. PubMed ID: 22130988
[TBL] [Abstract][Full Text] [Related]
31. Abiotic stress-associated miRNAs: detection and functional analysis.
Jeong DH; German MA; Rymarquis LA; Thatcher SR; Green PJ
Methods Mol Biol; 2010; 592():203-30. PubMed ID: 19802598
[TBL] [Abstract][Full Text] [Related]
32. Identification of forensically relevant body fluids using a panel of differentially expressed microRNAs.
Hanson EK; Lubenow H; Ballantyne J
Anal Biochem; 2009 Apr; 387(2):303-14. PubMed ID: 19454234
[TBL] [Abstract][Full Text] [Related]
33. Cerebrospinal fluid MicroRNA profiling using quantitative real time PCR.
Pacifici M; Delbue S; Kadri F; Peruzzi F
J Vis Exp; 2014 Jan; (83):e51172. PubMed ID: 24514260
[TBL] [Abstract][Full Text] [Related]
34. Gastric juice MicroRNAs as potential biomarkers for the screening of gastric cancer.
Cui L; Zhang X; Ye G; Zheng T; Song H; Deng H; Xiao B; Xia T; Yu X; Le Y; Guo J
Cancer; 2013 May; 119(9):1618-26. PubMed ID: 23335180
[TBL] [Abstract][Full Text] [Related]
35. Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Gandhi R; Healy B; Gholipour T; Egorova S; Musallam A; Hussain MS; Nejad P; Patel B; Hei H; Khoury S; Quintana F; Kivisakk P; Chitnis T; Weiner HL
Ann Neurol; 2013 Jun; 73(6):729-40. PubMed ID: 23494648
[TBL] [Abstract][Full Text] [Related]
36. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?
Ohrfelt A; Grognet P; Andreasen N; Wallin A; Vanmechelen E; Blennow K; Zetterberg H
Neurosci Lett; 2009 Feb; 450(3):332-5. PubMed ID: 19022350
[TBL] [Abstract][Full Text] [Related]
37. [Usage of Cerebrospinal Fluid for microRNA Analysis].
Kopková A; Šána J; Večeřa M; Knoflíčková D; Smrčka M; Slabý O; Fadrus P
Klin Onkol; 2018; 31(Supplementum1):158-160. PubMed ID: 29808693
[TBL] [Abstract][Full Text] [Related]
38. The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms.
O'Dowd ST; Ardah MT; Johansson P; Lomakin A; Benedek GB; Roberts KA; Cummins G; El Agnaf OM; Svensson J; Zetterberg H; Lynch T; Walsh DM
J Alzheimers Dis; 2013; 33(4):923-8. PubMed ID: 23034520
[TBL] [Abstract][Full Text] [Related]
39. CSF biomarkers in neurodegenerative diseases.
Mattsson N
Clin Chem Lab Med; 2011 Mar; 49(3):345-52. PubMed ID: 21303297
[TBL] [Abstract][Full Text] [Related]
40. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas.
Yabushita S; Fukamachi K; Tanaka H; Sumida K; Deguchi Y; Sukata T; Kawamura S; Uwagawa S; Suzui M; Tsuda H
Pancreas; 2012 Oct; 41(7):1013-8. PubMed ID: 22513294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
